ognizant Communication Corporation

ONCOLOGY RESEARCH
Featuring PRECLINICAL AND CLINICAL CANCER THERAPEUTICS

SUBSCRIPTION/PUBLISHING INFORMATION

Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics, An International Journal (ISSN 0965-0407) is published by Cognizant Communication Corporation, Robert Miranda, Publisher, 3 Hartsdale Rd., Elmsford, NY 10523-3701, USA, Tel 914-592-7720, Fax 914-592-8981, E-mail: Cogcomm@aol.com

Subscriptions: Published 12 numbers per year, subscriptions are sold on a calendar year basis by the volume number designated for that year. Professional Researchers Subscription: (US) $95.00, Rest of World (ROW) $115.00. Library and Institutions Subscriptions: (US) $1,050.00, (ROW) $1,075.00. Full text on line now available with paid subscription. Subscriber access code required (contact the publisher). Back Volumes, Volume 1-16, $900.00 per Volume, Single copy price $60.00. Payment by check in US dollars drawn on US Banks or International Money Order. Credit cards also accepted: Master Card/Visa only. Invoices will be issued on receipt of an institutional purchase order. Pay to the order of Cognizant Communication Corp., 3 Hartsdale Road, Elmsford, NY 10523, USA (EIN:22-3188698). Bank transfer: Routing # 021909300 - Hudson Valley Bank Account 061425-901.

Changes of address: Please supply old as well as new address.

Advertisement:Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics will accept advertisements. All advertisements are subject to approval by the Editor-in-Chief. For details and rates contact the Publisher.

Disclaimer: Although every effort is made by the publisher and editorial board to see that no inaccurate or misleading data, opinion, or statement appears in this journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the sole responsibility of the contributor or advertiser concerned. Accordingly, the publisher, editors, editorial board, and their respective employees, officers, and agents accept no responsibility or liability whatsoever for the consequences of any such inaccurate or misleading data, opinions, or statements.

Copyright Notice: It is a condition of publication that manuscripts submitted to this Journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for the articles is transferred to the publisher, if and when the article is accepted for publication. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform, or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording, or otherwise, without permission in writing from the copyright holder.

Photocopying information for users in the USA: The Item Fee Code for this publication indicates that authorization to photocopy item for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $90.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, MA 01923. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt, please contact Cognizant Communication Corporation. The Item Fee Code for this publication is 0965-0407/08 $90.00

Copyright © 2008, Cognizant Communication Corporation

Printed in the USA

Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics is indexed and abstracted in: Current Contents/Life Sciences, Science Search, Science Citation Index, Research Alert, MEDLARS, MEDLINE, Index Medicus, BIOSIS, SIIC (Sociedad Iberoamericana de Información Cientifica) Database, and CABS (Current Awareness in Biological Sciences).